Immunome Inc.
IM-1021
B-cell lymphoma
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for IM-1021 in B-cell lymphoma are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“expects to present initial data for IM-1021 in 2026.”